Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading 5.2% Higher Following Analyst Upgrade

Posted by Francis Steltz on Jul 7th, 2026

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) shares were up 5.2% on Tuesday after Royal Bank Of Canada raised their price target on the stock from $35.00 to $40.00. Royal Bank Of Canada currently has an outperform rating on the stock. Ultragenyx Pharmaceutical traded as high as $35.34 and last traded at $35.46. 389,069 shares were traded during trading, a decline of 83% from the average session volume of 2,262,907 shares. The stock had previously closed at $33.70.

Several other analysts have also recently weighed in on RARE. Morgan Stanley lifted their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, April 16th. Guggenheim dropped their price target on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Wedbush cut their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Finally, Wells Fargo & Company lifted their price objective on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.41.

Check Out Our Latest Stock Analysis on Ultragenyx Pharmaceutical

Insider Activity

In related news, Director Shehnaaz Suliman sold 5,740 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $25.12, for a total value of $144,188.80. Following the transaction, the director directly owned 27,951 shares of the company’s stock, valued at $702,129.12. This trade represents a 17.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Howard Horn sold 4,683 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $24.90, for a total transaction of $116,606.70. Following the transaction, the chief financial officer owned 110,342 shares of the company’s stock, valued at approximately $2,747,515.80. This represents a 4.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 19,319 shares of company stock valued at $476,837 in the last 90 days. 5.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently modified their holdings of RARE. Parallel Advisors LLC lifted its position in shares of Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,440 shares during the last quarter. Leonteq Securities AG raised its stake in Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,333 shares in the last quarter. Versant Capital Management Inc lifted its holdings in shares of Ultragenyx Pharmaceutical by 662.9% in the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,001 shares during the last quarter. Danske Bank A S acquired a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $39,000. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 1,845 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

The firm’s fifty day moving average is $25.87 and its 200-day moving average is $24.46. The company has a market capitalization of $3.50 billion, a P/E ratio of -5.83 and a beta of 0.31.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The company had revenue of $136.00 million during the quarter, compared to the consensus estimate of $158.19 million. During the same period in the previous year, the company earned ($1.57) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was down 2.2% on a year-over-year basis. As a group, analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.53 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

(Get Free Report)

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.